Federal Register / Vol. 89, No. 188 / Friday, September 27, 2024 / Notices 79299 

individuals and families who are 

receiving services under such programs 

or initiatives, the gaps in early 

childhood home visitation in the state, 

and the extent to which such programs 

or initiatives are meeting the needs of 

eligible families. 

(3) The state’s capacity for providing 

substance abuse treatment and 

counseling services to individuals and 

families in need of such treatment or 

services. 

The SIR provided guidance to states 

in updating their statewide needs 

assessments and submitting the required 

information to HRSA. States that elected 

not to apply or be awarded MIECHV 

funds were encouraged to work with 

nonprofit organizations that received 

awards to provide MIECHV-supported 

services within the state and determine 

whether they will submit their needs 

assessments directly or through the 

nonprofit organization awardee. HRSA 

and recipients providing MIECHV 

services within states used the 

information collected through the needs 

assessment update to ensure the 

continued provision of MIECHV home 

visiting services in at-risk communities. 

The information is also used to support 

program planning, improvement, and 

decision-making. States wishing to 

amend their needs assessment will be 

asked to provide new information and 

supporting data. HRSA will provide 

specific instructions on timeline and the 

amendment process to awardees who 

request to amend their needs assessment 

update in advance of their fiscal year 

2025 funding application. HRSA is not 

proposing any changes to the previously 

approved Needs Assessment SIR. 

Likely Respondents: MIECHV Program 

Awardees that are states, jurisdictions, 

and where applicable, nonprofit 

organizations providing services within 

states. Based on preliminary interest 

expressed by MIECHV awardees to date, 

HRSA anticipates that approximately 35 

of the 56 awardees may respond to this 

opportunity. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose, or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating, and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. Burden 

hours reflect that existing needs 

assessments will be amended rather 

than fully developed. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Maternal, Infant, and Early Childhood Home Visiting Program Statewide Needs Assessment Update—Amended 35 1 35 30 1,050 

Total .............................................................................. 35 ........................ 35 ........................ 1,050 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–22182 Filed 9–26–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI SingleSite and Pilot Clinical Trials Study Section. 

Date: October 23–24, 2024. 

Time: 8:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Canopy by Hilton 940 Rose Avenue 

North Bethesda, MD 20852. 

Contact Person: YingYing Li-Smerin, MD, 

Ph.D. Scientific Review Officer Office of 

Scientific Review/DERA National Heart, 

Lung, and Blood Institute, National Institutes 

of Health, 6705 Rockledge Drive,Room 207– 

P, Bethesda, MD 20892–7924 301–827–7942 

email: lismerin@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 13, 2024. 

Bruce A. George, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–22123 Filed 9–26–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01 Clinical 

Trial Not Allowed). 


lotter on DSK11XQN23PROD with NOTICES1